Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Double

<< Previous

Bullboard Posts

Next >>

Comment by colouramaon Aug 30, 2024 6:12pm

82 Views

Post# 36203508

RE:RE:RE:Double

Daudau, I am not suggesting any information given in the news releases is false - just if you assume adjusted EBITDA run rate is now at approximately $12 million * 2 = $24 million USD (just annualizing the latest adjusted EBITDA of about $3 million USD), then with EV = $360 million USD MCap + $40 million Debt = $400 million approximately, we get roughly EV/EBITDA = 400/24 approx 16.5 times.

I just thought that that sort of multiple seems to be more warranted after one or two quarters of concrete numbers.

But anyway I could be totally off base here. Envious but also happy to see CPH's growth!

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario